ROSEN, A Globally Recognized Law Firm, Announces Class Action Against ACELYRIN, INC. - SLRN - Investors

NEW YORK, Dec. 28, 2023 - Rosen Law Firm, internationally acclaimed for its dedication to investor rights, has issued a reminder to stockholders of ACELYRIN, INC. SLRN. The firm stresses the importance of contacting legal counsel prior to the approaching deadline of January 16, 2024, in relation to the securities class action lawsuit linked to the purchase of securities within the class period of May 4, 2023, to September 11, 2023.

Highlights of the Class Action

The lawsuit alleges improper conduct and potential violations of federal securities laws by SLRN, affecting investors who acquired shares during the specified period. Acelyrin, Inc. is a clinical-stage biopharma company, headquartered in Agoura Hills, California, focusing on the discovery, acquisition, and enhancement of groundbreaking medical treatments. The class action seeks to recover damages incurred by investors due to alleged misleading statements and potential lack of transparency which affected the value of their investments in SLRN.

Legal Recourse for Affected Investors

Shareholders affected by the price volatility and potential misinformation have a limited timeframe within which they can petition the court for lead plaintiff status. Rosen Law Firm advises SLRN investors to promptly secure legal representation to ensure their rights are protected within this class action lawsuit. The firm's extensive experience in securities class actions provides it with the capacity to effectively advocate on behalf of the company's shareholders.

About Acelyrin, Inc.

Acelyrin, Inc. SLRN, specializes in the advancement and commercialization of novel medical solutions. Maintaining a strong commitment to addressing unmet medical needs, SLRN operates at the forefront of clinical research, emphasizing the development of transformative medicines destined to make a significant impact on patient care.

Rosen, ACELYRIN, Investors